Reuse of drugs in the treatment of COVID-19
DOI:
https://doi.org/10.33448/rsd-v11i5.28484Keywords:
Chloroquine; Hydroxychloroquine; Ivermectin; Azithromycin; SARS-CoV-2.Abstract
After an outbreak of atypical pneumonia in the city of Wuhan, China, there were epidemiological alerts due to the unknown factor. On January 7, 2020, Chinese scientists isolated a strain of coronavirus, in which the etiologic agent was identified. It quickly spread around the world and, therefore, it was declared a pandemic on March 11, 2020. From then on, the need arises to search for treatments and prevention of the disease, through some existing drugs, such as Chloroquine, Hydroxychloroquine, Ivermectin and Azithromycin. Objective: The objective of this study is to discuss existing drugs used for the possible treatment of COVID-19, clarify their mechanisms of action and studies that prove their effectiveness or not. Methodology: The narrative review of the literature was based on a search in the Google Scholar, Capes, Scielo and PubMed journals databases published in the last 3 years, using the terms: “covid-19 drugs in vitro/in vivo”; "SARS-CoV-2"; “coronavirus”. Results: From the analysis of the articles, it can be noted that there is not enough evidence to prove the effectiveness of these drugs in the fight against COVID-19. The studies that showed results in combating SARS-CoV-2 were in vitro, in addition to being at higher doses than recommended for humans. Conclusion: Therefore, its therapeutic safety for the prevention and treatment of COVID-19 has not yet been clarified and determined, thus, its indiscriminate use can potentiate adverse effects.
References
Acevedo, K. . C., Pinzón, C., Barrera, A., Padilla, E. L., & Gonzalez, N. Y. (2020). Eficácia e segurança de cloroquina, hidroxicloroquina e azitromicina em pacientes com COVID-19. Resumo das evidências. Rev. Colomb. Nefrol, (7), 21-41.
Borba, M., Val, F., Sampaio, V. S., Alexandre, M., Melo, G. C., Brito, M., Mourão, M., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M., Hajjar, L. A., Pinto, R. C., Balieiro, A., Pacheco, A., Santos, J., Jr, Naveca, F. G., Xavier, M. S., Siqueira, A. M., Schwarzbold, A., Croda, J., … CloroCovid-19 Team (2020). Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA network open, 3(4), e208857. https://doi.org/10.1001/jamanetworkopen.2020.8857
Caly, L., Druce, J D, Catton, M G, Jans, D A & Wagstaff, K M (2020). O medicamento aprovado pela FDA, ivermectina, inibe a replicação do SARS-CoV-2 in vitro. Pesquisa antiviral , 178 , 104787. https://doi.org/10.1016/j.antiviral.2020.104787
Cavalcanti, A B, Zampieri, F G, Rosa, R G, Azevedo, L., Veiga, V C, Avezum, A., Damiani, LP, Marcadenti, A., Kawano-Dourado, L., Lisboa, T., Junqueira, D ., de Barros E Silva, P., Tramujas, L., Abreu-Silva, EO, Laranjeira, LN, Soares, AT, Echenique, LS, Pereira, AJ, Freitas, F., Gebara, O., … Coligação Covid -19 Investigadores do Brasil I (2020). Hidroxicloroquina com ou sem azitromicina na Covid-19 leve a moderada. The New England Journal of Medicine , 383 (21), 2041-2052. https://doi.org/10.1056/NEJMoa2019014.
Correia, L., & Fukushima, A R. (2020). Potencial Atividade Antiviral da Azitromicina: Revisão sistemática. Sanarmed. V03 P 97-99. Sanarcon, 2020.
Cox, M J, Loman, N., Bogaert, D., & O'Grady, J. (2020). Co-infecções: potencialmente letais e inexploradas na COVID-19. A Lanceta. Micróbio , 1 (1), e11. https://doi.org/10.1016/S2666-5247(20)30009-4.
Dhama, K., Khan, S., Tiwari, R., Sircar, S., Bhat, S., Malik, Y S, Singh, K P, Chaicumpa, W., Bonilla-Aldana, D K, & Rodriguez-Morales, A J (2020). Doença de Coronavírus 2019-COVID-19. Revisões de microbiologia clínica , 33 (4), e00028-20. https://doi.org/10.1128/CMR.00028-20.
Faiq I G , Sabeeh Mashhadani , Hend M Sayaly , Basim Dhawi Dakhil , Marwan M. AlMashhadani , Adnan M Aljabory , Hassan M Abbas , Mohammed Ghanim , Jawad I Rasheed Eficácia da ivermectina como terapia complementar no gerenciamento de COVID-19 (ensaio piloto) medRxiv 2020.07.07.20145979; doi:https://doi.org/10.1101/2020.07.07.20145979.
Fantini, J., Chahinian, H., & Yahi, N. (2020). Efeito antiviral sinérgico de hidroxicloroquina e azitromicina em combinação contra SARS-CoV-2: o que revelam estudos de dinâmica molecular de interações vírus-hospedeiro. Revista internacional de agentes antimicrobianos , 56 (2), 106020. https://doi.org/10.1016/j.ijantimicag.2020.106020
Gautret, P., Lagier, J C, Parola, P., Hoang, V T, Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V E, Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, JM, Brouqui, P., & Raoult, D. (2020). Hidroxicloroquina e azitromicina como tratamento de COVID-19: resultados de um ensaio clínico não randomizado aberto. Revista internacional de agentes antimicrobianos , 56 (1), 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949
He, F., Deng, Y., & Li, W. (2020). Coronavirus disease 2019: What we know?. Journal of medical virology, 92(7), 719–725. https://doi.org/10.1002/jmv.25766
Hussain, A H, Mohamed F. & Alajmi, M D. (2020). Tabish Rehman, Samira Amir, Impact of repurposed drugs on the symptomatic COVID-19 patients, Journal of Infection and Public Health, Volume 14, Issue 1, 2021, Pages 24-38, ISSN 1876-0341, https://doi.org/10.1016/j.jiph.2020.11.009.
Jean, S. S., Lee, P. I., & Hsueh, P. R. (2020). Treatment options for COVID-19: The reality and challenges. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 53(3), 436–443. https://doi.org/10.1016/j.jmii.2020.03.034.
Jean, S S, & Hsueh, P R (2020). Medicamentos antigos e reaproveitados para o tratamento do COVID-19. Revisão de especialistas de terapia anti-infecciosa , 18 (9), 843 847. https://doi.org/10.1080/14787210.2020.1771181.
Katzung, Bertram G, Trevor, & Anthony J.(2017). Farmacologia Básica e Clínica. 13. ed. Porto Alegre: AMGH, 2017.
Kramer, D. G., Cavalcanti Junior, G. B., & Pereira, N. de S. (2020). Hidroxicloroquina: uso potencial em coronaviroses?. Revista Contexto &Amp; Saúde, 20(38), 16–21. https://doi.org/10.21527/2176-7114.2020.38.16-21.
Koche, J. C. (2011). Fundamentos de metodologia científica. Petrópolis: Vozes.
Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hu, Z., Zhong, W., & Wang, M. (2020). A hidroxicloroquina, um derivado menos tóxico da cloroquina, é eficaz na inibição da infecção por SARS-CoV-2 in vitro. Descoberta de células , 6 , 16. https://doi.org/10.1038/s41421-020-0156-0.
López-Medina, E., López, P., Hurtado, IC, Dávalos, DM, Ramirez, O., Martínez, E., Díazgranados, J A, Oñate, J M, Chavarriaga, H., Herrera, S., Parra, B., Libreros, G., Jaramillo, R., Avendaño, AC, Toro, D F, Torres, M., Lesmes, M C, Rios, CA, & Caicedo, I. (2021). Efeito da ivermectina no tempo de resolução dos sintomas entre adultos com COVID-19 leve: um ensaio clínico randomizado. JAMA , 325 (14), 1426-1435. https://doi.org/10.1001/jama.2021.3071.
Mercuro, N. J., Yen, C. F., Shim, D. J., Maher, T. R., McCoy, C. M., Zimetbaum, P. J., & Gold, H. S. (2020). Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA cardiology, 5(9), 1036–1041. https://doi.org/10.1001/jamacardio.2020.1834.
Mohan P, Sinha S, Uppal R. Papel da ivermectina na COVID-19: Wishful thinking ou otimismo científico. J Mar Med Soc 2020;22, Supl S1:27-31.
Navarro, M., Camprubí, D., Requena-Méndez, A., Buonfrate, D., Giorli, G., Kamgno, J., Gardon, J., Boussinesq, M., Muñoz, J., & Krolewiecki, A. (2020). Safety of high-dose ivermectin: a systematic review and meta-analysis. The Journal of antimicrobial chemotherapy, 75(4), 827–834. https://doi.org/10.1093/jac/dkz524
Nih. NTM-CBI. (2020). Pub Chem: Resumo Composto. Azitromicina. 2020a. Disponível em: https://pubchem.ncbi.nlm.nih.gov/compound/447043.
Phelan, A L, Katz, R., & Gostin, L O (2020). O novo coronavírus originário de Wuhan, China: desafios para a governança global da saúde. JAMA , 323 (8), 709-710. https://doi.org/10.1001/jama.2020.1097.
Pillay T. S. (2020). Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Journal of clinical pathology, 73(7), 366–369. https://doi.org/10.1136/jclinpath-2020-206658.
Rajter, J. C., Sherman, M. S., Fatteh, N., Vogel, F., Sacks, J., & Rajter, J. (2020, October 12). Uso de ivermectina está associado a menor mortalidade em pacientes hospitalizados com doença de coronavírus 2019. Chest Journal, 85-92. https://doi.org/10.1016/j.chest.2020.10.009.
Schmith, V D, Zhou, J J & Lohmer, L. (2020). A dose aprovada de ivermectina isolada não é a dose ideal para o tratamento do COVID-19. Farmacologia clínica e terapêutica , 108 (4), 762-765. https://doi.org/10.1002/cpt.1889.
Schrezenmeier, E., & Dörner, T. (2020). Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature reviews. Rheumatology, 16(3), 155–166. https://doi.org/10.1038/s41584-020-0372-x.
Sharun, K., Shyamkumar, T S, Aneesha, V A, Dhama, K., Pawde, AM & Pal, A. (2019). Aplicações terapêuticas atuais e modulações farmacocinéticas da ivermectina. Veterinary world , 12 (8), 1204-1211. https://doi.org/10.14202/vetworld.2019.1204-1211.
Shereen, M A, Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020). Infecção por COVID-19: Origem, transmissão e características dos coronavírus humanos. Journal of advanced research , 24 , 91-98. https://doi.org/10.1016/j.jare.2020.03.005.
Spinelli, F. R., Ceccarelli, F., Di Franco, M., & Conti, F. (2020). To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic. Annals of the rheumatic diseases, 79(5), 666–667. https://doi.org/10.1136/annrheumdis-2020-217367.
Tanni, Suzana E; Bacha, Hélio A; Naime, Alexandre; Bernardo, & Wanderley M. (2001). Uso de hidroxicloroquina para prevenir a infecção por SARS-CoV-2 e tratar COVID-19 leve: revisão sistemática e meta-análise. JBP, [S. l.], p. 1-11, 15 jul. 2021.
Vanzeler, M. et al. Utilização De Azitromicina Para O Tratamento Da Covid-19: Uma Visão Crítica. Revista Científica Multidisciplinar Núcleo do Conhecimento. ed. 04, Vol. 09, pp. 05-21. 2021.
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 323(11), 1061–1069. https://doi.org/10.1001/jama.2020.1585
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research, 30(3), 269–271. https://doi.org/10.1038/s41422-020-0282-0.
Ye, Q., Wang, B., & Mao, J. (2020). The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. The Journal of infection, 80(6), 607–613. https://doi.org/10.1016/j.jinf.2020.03.037.
Zhang, J., Ma, X., Yu, F., Liu, J., Zou, F., Pan, T., & Zhang, H. (2020). Teicoplanin potently blocks the cell entry of 2019-nCoV. BioRxiv.
Zhou, Fei.; Yu, Tring.; Du, Ronghui.; Fan, Guohui.; Lui, Ying.; & Xiang, Jie (2020). Curso clinic e fatores de risco para mortalidades de pacientes adultos internados com COVID-19 em Whuan, China: um estudo de coorte retrospectivo. The Lancet. 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3.
Zhu N, Zhang D, Wang W, Li X, Yang B, & Song J (2020). A novel coronavirus from patients with pneumonia in China, 2019. The New England Journal of Medicine. 2020;382:727-33.
Zou, L., Dai, L., Zhang, X., Zhang, Z., & Zhang, Z. (2020). Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. Archives of pharmacal research, 43(8), 765–772. https://doi.org/10.1007/s12272-020-01258-7
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Alessandra Isabô Neri; Lílian Carla Carneiro; Cristiene Costa Carneiro; Aroldo Vieira de Moraes Filho; Lee Chen-Chen
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
